• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

    29.21 +0.76 (+2.67%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about ACADIA Pharmaceuticals Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    18 19 Next >
    ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 Earnings Beat, Stock Rises on Raised Guidance ↗
    Via Chartmill
    Topics Earnings
    News headline image
    ACADIA Pharmaceuticals Q2 Earnings Call Highlights ↗
    ACADIA Pharmaceuticals (NASDAQ:ACAD) reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? ↗
    Acadia Pharmaceuticals specializes in CNS therapies; a key insider recently trimmed their stake amid ongoing product pipeline developments. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Why Acadia Pharmaceuticals Stock Is Soaring Today ↗
    An approval of one of its drugs for a major market is now looking likely. 
    Via The Motley Fool
    Traders are paying attention to the gapping stocks in Friday's session. ↗
    Via Chartmill
    News headline image
    Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday ↗
    Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc... 
    Via Benzinga
    News headline image
    DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth ↗
    ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide... 
    Via MarketBeat
    News headline image
    ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms ↗
    ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders,... 
    Via MarketBeat
    News headline image
    Acadia (ACAD) Q1 2026 Earnings Transcript ↗
    Acadia (ACAD) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
    Via MarketMinute
    News headline image
    Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
    The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most... 
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
    Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has... 
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
    PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
    This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach. 
    Via The Motley Fool
    Topics Regulatory Compliance
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    18 19 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.